{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T01:08:07Z","timestamp":1777770487146,"version":"3.51.4"},"reference-count":36,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203878"],"award-info":[{"award-number":["82203878"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372712"],"award-info":[{"award-number":["82372712"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573405"],"award-info":[{"award-number":["82573405"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Overseas Training Program for Medical Science and Technology Talents of Henan Provincial Health Commission","award":["HNMOT2024079"],"award-info":[{"award-number":["HNMOT2024079"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M731011"],"award-info":[{"award-number":["2023M731011"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health and Technology Innovation Leadersin of Henan Province","award":["YXKC2022005"],"award-info":[{"award-number":["YXKC2022005"]}]},{"name":"Henan Provincial Medical Science and Technology Research Program Major Project","award":["SBGJ202501002"],"award-info":[{"award-number":["SBGJ202501002"]}]},{"name":"Henan Provincial-Ministerial Joint Youth Project for Medical Science and Technology Research","award":["SBGJ202403021"],"award-info":[{"award-number":["SBGJ202403021"]}]},{"name":"Henan Province International Training Program for High-level Talents","award":["GCC2026043"],"award-info":[{"award-number":["GCC2026043"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,4,9]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although HER2-targeted therapies have dramatically improved outcomes for patients with HER2-positive breast cancer, the immunosuppressive tumor microenvironment remains a major barrier to effective immunotherapy in this subtype. Therefore, we sought to develop a new bispecific antibody targeting both HER2 and C-type lectin domain family 5 member A (CLEC5A), a pattern recognition receptor on innate immune cells like macrophages, aiming to alter the tumor immune environment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CLEC5A-HER2 bispecific antibodies were generated and evaluated for binding properties, macrophage activation, and phagocytic activity in vitro. Anti-tumor efficacy was assessed in multiple syngeneic mouse models, including orthotopic breast cancer models, with mechanistic studies and immune checkpoint inhibitor combinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The CLEC5A-HER2 bispecific antibody was more effective in anti-tumor activity than either monotherapies or combinations of individual antibodies in various syngeneic models, including an orthotopic breast cancer model. Mechanistically, it converted \u201ccold\u201d tumors into \u201chot\u201d tumors by promoting macrophage-mediated phagocytosis, repolarizing tumor-associated macrophages toward an M1-like phenotype, and enhancing antigen presentation and T-cell recruitment. This immune remodeling restored the CXCL9\/10-CXCR3 axis, increased CD8+ T\u2009cell infiltration, reduced regulatory T cells, and underpinned a T cell-dependent anti-tumor response. Interestingly, combination therapy with CTLA-4 and PD-1 blockade exhibited strong synergistic effects without significant toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results identify the CLEC5A-HER2 bispecific antibody as a potential immunotherapy for HER2-positive cancers by effectively engaging both innate and adaptive immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-014799","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:35:16Z","timestamp":1777480516000},"page":"e014799","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["C-type lectin domain family 5 member A-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy"],"prefix":"10.1136","volume":"14","author":[{"given":"Lei","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Centre, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China"},{"name":"Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dechuang","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Centre, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Centre, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Centre, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Centre, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xilong","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Centre, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuihua","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Centre, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuhui","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Centre, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3878-1258","authenticated-orcid":false,"given":"ZhenZhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Centre, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2026042909351046000_14.4.e014799.1","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-019-0069-2","article-title":"Targeted therapeutic options and future perspectives for HER2-positive breast cancer","volume":"4","author":"Wang","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"2026042909351046000_14.4.e014799.2","doi-asserted-by":"crossref","unstructured":"Pernas S , Tolaney SM . HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol 2019;11. doi:10.1177\/1758835919833519","DOI":"10.1177\/1758835919833519"},{"key":"2026042909351046000_14.4.e014799.3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092136","article-title":"Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives","volume":"14","author":"Agostinetto","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026042909351046000_14.4.e014799.4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds200"},{"key":"2026042909351046000_14.4.e014799.5","doi-asserted-by":"crossref","unstructured":"Huang J , Zhu Y , Zeng W , et al . Single-cell transcriptome analysis reveals the malignant characteristics of tumour cells and the immunosuppressive landscape in HER2-positive inflammatory breast cancer. J Exp Clin Cancer Res 2025;44. doi:10.1186\/s13046-025-03454-z","DOI":"10.1186\/s13046-025-03454-z"},{"key":"2026042909351046000_14.4.e014799.6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27648"},{"key":"2026042909351046000_14.4.e014799.7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126526","article-title":"Tumor-Associated Macrophages as Multifaceted Regulators of Breast Tumor Growth","volume":"22","author":"Munir","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026042909351046000_14.4.e014799.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2017.04.010"},{"key":"2026042909351046000_14.4.e014799.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.169"},{"key":"2026042909351046000_14.4.e014799.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.01.003"},{"key":"2026042909351046000_14.4.e014799.11","doi-asserted-by":"crossref","unstructured":"Lin Y , Xu J , Lan H . Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol 2019;12. doi:10.1186\/s13045-019-0760-3","DOI":"10.1186\/s13045-019-0760-3"},{"key":"2026042909351046000_14.4.e014799.12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001341","article-title":"Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer","volume":"9","author":"Li","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026042909351046000_14.4.e014799.13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.643771","article-title":"Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"key":"2026042909351046000_14.4.e014799.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105111"},{"key":"2026042909351046000_14.4.e014799.15","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9473497","article-title":"Elevated Expression of C-Type Lectin Domain Family 5-Member A (CLEC5A) and Its Relation to Inflammatory Parameters and Disease Course in Adult-Onset Still\u2019s Disease","volume":"2020","author":"Chen","year":"2020","journal-title":"J Immunol Res"},{"key":"2026042909351046000_14.4.e014799.16","doi-asserted-by":"publisher","DOI":"10.1038\/nature07013"},{"key":"2026042909351046000_14.4.e014799.17","doi-asserted-by":"crossref","unstructured":"Chen S-T , Li F-J , Hsu T , et al . CLEC5A is a critical receptor in innate immunity against Listeria infection. Nat Commun 2017;8. doi:10.1038\/s41467-017-00356-3","DOI":"10.1038\/s41467-017-00356-3"},{"key":"2026042909351046000_14.4.e014799.18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101352"},{"key":"2026042909351046000_14.4.e014799.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-017-1336-z","article-title":"The macrophage C-type lectin receptor CLEC5A (MDL-1) expression is associated with early plaque progression and promotes macrophage survival","volume":"15","author":"Xiong","year":"2017","journal-title":"J Transl Med"},{"key":"2026042909351046000_14.4.e014799.20","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg5568"},{"key":"2026042909351046000_14.4.e014799.21","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax3160","article-title":"B7-H3\u00d74-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes","volume":"7","author":"You","year":"2021","journal-title":"Sci Adv"},{"key":"2026042909351046000_14.4.e014799.22","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ijbiomac.2020.11.058","article-title":"Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials","volume":"167","author":"Hosseini","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"2026042909351046000_14.4.e014799.23","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0002"},{"key":"2026042909351046000_14.4.e014799.24","doi-asserted-by":"publisher","DOI":"10.1042\/bst0300507"},{"key":"2026042909351046000_14.4.e014799.25","doi-asserted-by":"crossref","first-page":"107986","DOI":"10.1016\/j.pharmthera.2021.107986","article-title":"Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach","volume":"231","author":"Chamseddine","year":"2022","journal-title":"Pharmacol Ther"},{"key":"2026042909351046000_14.4.e014799.26","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.217"},{"key":"2026042909351046000_14.4.e014799.27","first-page":"4","article-title":"Tinker, tailor, soldier, cell: the role of C-type lectins in the defense and promotion of disease","volume":"14","author":"Arnold","year":"2022","journal-title":"Protein Cell"},{"key":"2026042909351046000_14.4.e014799.28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00227","article-title":"C-Type Lectin-Like Receptors As Emerging Orchestrators of Sterile Inflammation Represent Potential Therapeutic Targets","volume":"9","author":"Chiffoleau","year":"2018","journal-title":"Front Immunol"},{"key":"2026042909351046000_14.4.e014799.29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.14377","article-title":"Macrophage targeting in cancer","volume":"1499","author":"Lopez-Yrigoyen","year":"2021","journal-title":"Ann N Y Acad Sci"},{"key":"2026042909351046000_14.4.e014799.30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8110101","article-title":"Targeting the TAM Receptors in Leukemia","volume":"8","author":"Huey","year":"2016","journal-title":"Cancers (Basel)"},{"key":"2026042909351046000_14.4.e014799.31","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-021-03113-9","article-title":"The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling","volume":"19","author":"Schlam","year":"2021","journal-title":"J Transl Med"},{"key":"2026042909351046000_14.4.e014799.32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1815"},{"key":"2026042909351046000_14.4.e014799.33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1158\/2326-6066.CIR-24-1046","article-title":"The Problem with Syngeneic Mouse Tumor Models","volume":"13","author":"Lonberg","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"2026042909351046000_14.4.e014799.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246168","article-title":"A novel mouse model for checkpoint inhibitor-induced adverse events","volume":"16","author":"Adam","year":"2021","journal-title":"PLoS One"},{"key":"2026042909351046000_14.4.e014799.35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026042909351046000_14.4.e014799.36","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6074.CIMM25-PR-07","article-title":"Abstract PR-07: Immunosuppressive \u03b3\u03b4 T cells limit anti-tumor immunity in ICI-resistant tumors from autoimmune-prone mice","volume":"13","author":"Hansen","year":"2025","journal-title":"Cancer Immunol Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-014799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:35:21Z","timestamp":1777480521000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-014799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,29]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/jitc-2026-014799"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-014799","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}